Estimates Revisions Ovid Therapeutics Inc.
Stocks
OVID
US6904691010
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.350 USD | +0.86% |
|
+1.95% | +44.17% |
| 07-08 | Ovid Therapeutics Names Kevin Norrett Chief Business Officer, Promotes CFO and Chief Strategy Officer | MT |
| 07-08 | Ovid Therapeutics Inc. Announces Executive Changes, Effective July 6, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- OVID Stock
- Consensus Ovid Therapeutics Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
